1008 related articles for article (PubMed ID: 23868789)
1. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
2. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
3. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
4. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
5. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
6. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
8. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
11. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
13. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
14. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
16. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
17. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
[TBL] [Abstract][Full Text] [Related]
18. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
20. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
